In a meta-analysis of patients undergoing pRARP or EBRT for all risk prostate cancer, both OS and CSS were better for patients undergoing pRARP and BCR free survival was better for patients undergoing EBRT at 10 years (21). This evidence concerns the gene BCR and prostate carcinoma.